Skip to main content

and
  1. Article

    Open Access

    A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study

    Many studies have recently reported the association of concomitant medications with the response and survival in patients with non-small-cell lung cancer (NSCLC) treated with cancer immunotherapy. However, the...

    Kazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori, Shinichiro Shimamatsu in BMC Cancer (2022)

  2. Article

    Open Access

    Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

    This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid...

    Kan Yonemori, Kenji Tamura, Makoto Kodaira in Cancer Chemotherapy and Pharmacology (2016)

  3. Article

    Open Access

    Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors

    Investigate the safety and tolerability of AZD5363 and define a recommended dose for evaluation in Japanese patients with advanced solid malignancies.

    Kenji Tamura, Jun Hashimoto, Yuko Tanabe in Cancer Chemotherapy and Pharmacology (2016)

  4. No Access

    Article

    Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy

    Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that responds poorly to chemotherapy. Although treatment with pemetrexed in combination with cisplatin serves as first-line chemotherapy for MPM,...

    Gouji Toyokawa, Mitsuhiro Takenoyama in International Journal of Clinical Oncology (2014)

  5. No Access

    Article

    Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

    AZD7762, a potent Chk1/Chk2 inhibitor, has shown chemosensitizing activity with gemcitabine in xenograft models.

    Takashi Seto, Taito Esaki, Fumihiko Hirai in Cancer Chemotherapy and Pharmacology (2013)